Targeted vitamin D3 therapy shown to cut second heart attack risk by 50% in groundbreaking trial

In a healthcare system dependent on expensive, patent-protected drugs, a new clinical breakthrough offers a stunning rebuke: a simple, affordable vitamin, when used correctly, can dramatically alter the grim statistics of heart disease. Presented at the 2025 American Heart Association Scientific Sessions, research from Intermountain Health reveals that a personalized “target to treat” strategy with vitamin D3 slashes the risk of a recurrent heart attack by approximately half. 

Key points:

• A new clinical trial found personalized vitamin D3 supplementation reduced the risk of a second heart attack by about 50%.
• The “target to treat” approach involved regular blood testing to adjust doses, aiming for levels above 40 ng/mL, with over half of patients needing 5,000 IU daily.
• The study observed no adverse effects from the higher, targeted dosing.
• This challenges previous failed trials that used standard, low doses without monitoring individual patient levels.
• The findings were presented in November 2025 and are pending peer-reviewed publication.
• The study aligns with previous meta-analyses linking vitamin D intake to improved cardiovascular outcomes.

Personalized dosing unlocks vitamin D’s true power

The study, led by principal investigator Heidi May, Ph.D., a cardiovascular epidemiologist at Intermountain Health, followed 630 heart attack patients with an average age of 62. Participants were randomized into two groups: one received standard post-heart attack care, while the other received targeted vitamin D3 management.

The objective was clear and personalized. Instead of handing out a uniform, often ineffective low dose, researchers aimed to raise each patient’s blood level of 25-hydroxyvitamin D to above 40 nanograms per milliliter. Regular blood tests, sometimes as frequent as every three months, were used to adjust the dosage until the target was achieved and maintained.

For context, while general sufficiency is defined at 30 ng/mL, a staggering 85% of the heart attack patients in the trial began with insufficient levels below 40 ng/mL. To reach the therapeutic target, more than 50% of patients required an initial dose of 5,000 international units daily, a level far exceeding the standard Recommended Dietary Allowance of 600-800 IU.

TARGET-D trial builds on previous vitamin D research showing improved cardiovascular outcomes

This tailored approach is the critical factor that separates this trial from past research that dismissed vitamin D’s cardiovascular benefits. Dr. May explicitly noted the flaw in prior science. “Previous studies just gave patients supplementation without regularly checking blood levels of vitamin D to determine what supplementation achieved,” she stated.

Those studies, often giving blanket low doses to populations with varying baseline levels, were destined to show null results. This new methodology acknowledges a fundamental truth of human biochemistry: individual needs vary wildly. The research, dubbed the TARGET-D trial, validates what integrative medical practitioners have long argued: it is the achieved blood level of a nutrient, not the arbitrary dose ingested, that determines its biological effect. This principle dismantles the simplistic, drug-based model applied to nutrition.

Vitamin D’s role extends far beyond bone health. It is a potent regulator of inflammation, a key driver of arterial plaque formation and instability. It supports endothelial function, the health of the blood vessel lining, and influences blood pressure and glucose metabolism.

A 2025 narrative review in Nutrients consolidated evidence, stating that low vitamin D status is consistently associated with higher cardiovascular risk and mortality, and that the nutrient plays a plausible role in modulating disease pathways. The Intermountain trial translates this biological plausibility into hard clinical outcome. While the composite rate of major adverse cardiac events, which included stroke and heart failure hospitalization, did not differ significantly between groups, the specific, crushing risk of another heart attack was cut in half. In a nation where someone suffers a heart attack nearly every 40 seconds and 200,000 of those are recurrent events, this represents a monumental shift in preventive strategy.

Sources include:

MindBodyGreen.com

News.IntermountHealth.org

Pubmed.gov